Precision Epigenomics Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Precision Epigenomics Inc. - overview
Established
2021
Location
Tucson, AZ, US
Primary Industry
Medical Devices & Equipment
About
Based in Arizona, US, and founded in 2021 by co-founder and CEO Mark A. Nelson, PhD, Precision Epigenomics Inc. , formerly known as DesertDX, LLC, operates as a provider of the EPISEEK liquid biopsy test to adults, particularly those aged 45 and older, for early cancer detection. In March 2024, Precision Epigenomics Inc.
raised USD 1. 7 million in Series A funding led by Shaffer Capital, LLC, with participation from DVRGNT Ventures. The company provides early cancer detection services, including the EPISEEK test, which identifies specific cancer-related DNA methylation patterns from a simple blood draw. The test can detect up to 20 types of cancer, including in early stages.
Additionally, the firm also provides comprehensive test result interpretation and support services for healthcare providers.
Current Investors
DVRGNT Ventures, Shaffer Capital, LLC
Primary Industry
Medical Devices & Equipment
Sub Industries
Diagnostic, Medical & Imaging Laboratories, Oncology/Cancer Treatment, Diagnostic Equipment
Website
www.precision-epigenomics.com/
Verticals
Manufacturing
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.